Edition:
India

Summit Therapeutics PLC (SMMT.OQ)

SMMT.OQ on NASDAQ Stock Exchange Global Market

1.48USD
16 Jan 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.48
Open
$1.47
Day's High
$1.50
Day's Low
$1.47
Volume
2,588
Avg. Vol
7,780
52-wk High
$15.75
52-wk Low
$1.10

Latest Key Developments (Source: Significant Developments)

Summit Therapeutics enters exclusive licence agreement with Eurofarma Laboratórios
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Summit Therapeutics Plc ::SUMMIT THERAPEUTICS PLC HAS ENTERED INTO AN EXCLUSIVE LICENCE AND COMMERCIALISATION AGREEMENT WITH EUROFARMA LABORATÓRIOS SA.AGREEMENT GRANTS EUROFARMA LABORATÓRIOS SA RIGHTS IN LATIN AMERICA TO SUMMIT'S PRECISION ANTIBIOTIC RIDINILAZOLE IN DEVELOPMENT FOR THE TREATMENT OF CDI.SUMMIT RETAINS COMMERCIALISATION RIGHTS IN ALL OTHER COUNTRIES.RIDINILAZOLE IS A TARGETED ANTIBIOTIC THAT HAS THE POTENTIAL AS A FRONTLINE THERAPY TO TREAT INITIAL INFECTION AND PRESERVE PATIENTS' MICROBIOMES TO REDUCE THE RATE OF RECURRENT CDI .  Full Article

CORRECTED-Bangladesh's second LNG terminal to start in March; supply faces hiccups

SINGAPORE/DHAKA, Jan 15 Bangladesh's second liquefied natural gas (LNG) terminal is expected to start operations in mid-March though domestic pipeline constraints means it will be unable to fully supply gas demand to the country's capital Dhaka.

No consensus analysis data available.